results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
Limited (“the Company”) would like to clarify the consolidated financial statements of the Company for the 1st quarter of fiscal year 2017 ended as of March 31, 2017, which can be summarized as follows
quarter ended 31 March 2019 which had been reviewed by the independent auditor as follows: Consolidated financial statements The Group reported profit attributable to owners of the Company for Q1/2019 in
the “Group”) for the second quarter ended 30 June 2019 which had been reviewed by the independent auditor as follows: Consolidated financial statements The Group reported profit attributable to owners
(collectively as the “Group”) for the third quarter ended 30 September 2019 which had been reviewed by the independent auditor as follows: Consolidated financial statements The Group reported profit attributable
Company’s Q3-2020 (Jul-Sep) operating results based on its reviewed consolidated financial statements ended 30 Sep 2020 as follows. Highlights on Q3-2020 Operating Results Unit : Million Baht Q3-20 Q3-19 Q2
Q1-2021 (Jan-Mar) operating results based on its reviewed consolidated financial statements ended 31 March 2021 as follows. Highlights on Q1-2021 Operating Results Unit : Million Baht Q1-21 Q1-20 Q4-20
Q1-2020 (Jan-Mar) operating results based on its reviewed consolidated financial statements ended 31 March 2020 as follows. Highlights on Q1-2020 Operating Results Unit : Million Baht Q1-20 Q1-19 Q4-19
Baht) Consolidated Financial Statements 3Q'19 3Q'18 % YTD YTD % Change 2019 2018 Change Total Revenue 452.8 443.4 2.1% 1,387.3 1,288.9 7.6% - Utilities Business 449.8 442.3 1.7% 1,381.4 1,287.0 7.3
% 2.2% 29.9% 27.2% (2.7%) Net profit margin1 (%) 17.7% 8.1% (9.6%) 19.7% 7.1% (12.6%) Number of branches as at Dec 312 38 39 3% 38 39 3% 2019 2020 Change +/(-) Change +/(-) Q4/19 Q4/20 Operating highlight